Alexis Harper
Adult Health · Olympia Fields, ILNPI 1689909749
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,746 of the $3,789 with a category attached, or 72.5%. 25 manufacturers reported payments, led by Medtronic at 32.3% of the total.
Across 139 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$360
- Abbott$351
- Lilly USA, LLC$331
- Corcept Therapeutics$195
- Sanofi-aventis U.S. LLC$166
- plus $1K from 19 others
What the payments were for
- Travel & lodging$99826%
- Food & beverage$2,74672%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 10 | $1,224 |
| Novo Nordisk | 19 | $360 |
| Abbott | 21 | $351 |
| Lilly USA, LLC | 16 | $331 |
| Corcept Therapeutics | 9 | $195 |
| Sanofi-aventis U.S. LLC | 9 | $166 |
| Dexcom, Inc. | 6 | $133 |
| Boehringer Ingelheim | 6 | $116 |
| Insulet Corporation | 5 | $115 |
| Tandem Diabetes Care, Inc. | 4 | $100 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Johnson & Johnson(2 entities) | 5 | $79 |
| Bayer | 2 | $71 |
| Sequel Med Tech, LLC | 3 | $61 |
| Ascendis Pharma Endocrinology Inc | 3 | $57 |
| AstraZeneca(2 entities) | 2 | $49 |
| Antares Pharma, Inc. | 2 | $40 |
| Ascensia Diabetes Care US Inc. | 2 | $39 |
| Radius Health, Inc. | 1 | $33 |
| AbbVie | 2 | $29 |
| Embecta Corp. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| BETA Bionics, Inc. | 1 | $18 |
| Neurelis, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$939
How this compares
$3,789 in reported general payments places this provider in the 85th percentile of 553 adult health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 454 | $834,490 |
| JardianceEmpagliflozin | 411 | $546,596 |
| TrulicityDulaglutide | 176 | $317,782 |
| MounjaroTirzepatide | 139 | $245,751 |
| JanuviaSitagliptin Phosphate | 110 | $128,928 |
| RybelsusSemaglutide | 47 | $88,838 |
| FarxigaDapagliflozin Propanediol | 66 | $87,238 |
| Tresiba Flextouch U-200Insulin Degludec | 73 | $85,493 |
| TradjentaLinagliptin | 77 | $82,473 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $52,478 |
| Humalog Kwikpen U-200Insulin Lispro | 39 | $47,091 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 89 | $46,802 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 329 | $43,267 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 274 | $40,832 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $35,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $360 | $935,765530 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $116 | $648,633500 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $331 | $563,533315 claims |
| AstraZenecaFarxiga | $49 | $87,23866 claims |
| AbbVieSynthroid | $29 | $2,99238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 553 adult health providers in Illinois.
Other adult health in Olympia Fields
- Samantha CarneyOlympia Fields$10K
- Debra MangrumOlympia Fields$7K
- Kimberly KearnsHoffman Estates$531K
- Leslie ForresterArlington Heights$97K
- Colleen FolkersChicago$86K
- Matthew BurkeChicago$44K
- Jacklyn GideonChicago$38K
- Jennifer GreenfieldChicago$35K
- Tammy PomaChicago$32K
- Tammy BrownNorth Chicago$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.